ResearcherInstitute of Life SciencesNo recent work listed
Madhuri Dutta
Matched on OpenAlex author ID A5057101196. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2022: 2 papers · 2023: 1 paper
Papers 3
- Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome. Co-author DOI 10.1007/s00262-023-03562-9↗
- ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2022.10.021↗
- MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. Co-author DOI 10.1016/j.lfs.2022.120592↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Debasish Mohapatra · 3 shared papers, 2022–2023 · strength 0.57
- Paper ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells. DOI 10.1016/j.bbrc.2022.10.021↗
- Paper MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. DOI 10.1016/j.lfs.2022.120592↗
- Paper Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with… DOI 10.1007/s00262-023-03562-9↗
- Shantibhusan Senapati · 3 shared papers, 2022–2023 · strength 0.57
- Paper ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells. DOI 10.1016/j.bbrc.2022.10.021↗
- Paper MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. DOI 10.1016/j.lfs.2022.120592↗
- Paper Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with… DOI 10.1007/s00262-023-03562-9↗
- Anasuya Roychowdhury · 2 shared papers, 2022 · strength 0.39
- Biswajit Das · 1 shared paper, 2022 · strength 0.19
- Deepti Parida · 1 shared paper, 2023 · strength 0.18
- Aliva Prity Minz · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.